Form 4: Samsara BioCapital Acquires 294,000 Shares of CARGO Therapeutics, Inc.

Samsara BioCapital, through its affiliated entities, acquired 294,000 shares of CARGO Therapeutics at $17 per share, increasing its indirect beneficial ownership to 4,415,689 shares.

Summary

• On May 30, 2024, Samsara BioCapital GP, LLC, along with Samsara BioCapital, L.P. and Srinivas Akkaraju, reported changes in their beneficial ownership of CARGO Therapeutics, Inc. shares.
• Samsara BioCapital, L.P. acquired 294,000 shares of Common Stock at a price of $17 per share.
• Following the transaction, Samsara BioCapital, L.P. indirectly beneficially owns 4,415,689 shares.
• Samsara BioCapital GP, LLC is the general partner of Samsara BioCapital, L.P. and may be deemed to beneficially own the shares held by Samsara BioCapital, L.P..
• Srinivas Akkaraju has voting and investment power over the shares held by Samsara BioCapital, L.P. and may be deemed to beneficially own the shares held by Samsara BioCapital, L.P..

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a transaction. The increased stake could be seen as positive, but without further context, it's hard to gauge the overall impact.

Positives

• Samsara BioCapital's increased investment in CARGO Therapeutics could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

This filing reflects ongoing investment activity in the biotechnology sector, where firms like Samsara BioCapital actively manage their portfolios through strategic acquisitions.

Stakeholder Impact

• Shareholders may view this acquisition positively, as it signals confidence from a major investor.
• The increased ownership stake could potentially influence future corporate decisions.

Key Dates